ClinicalTrials.gg
CompletedNCT01344057Updated Apr 28, 2023Results posted

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

A Phase 2 interventional study of Seasonal Influenza Vaccine in Seasonal Influenza, sponsored by Novartis Vaccines. Completed at 6 sites in Italy. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-28.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Influenza, Human by Novartis — none open to participants now, none under way, none of them phase 3. Influenza, Human · Novartis.

Enrollment
85th of 97
63 · median 270
Started
2011
with 4 others
Phase 2
42 of 101
none open now
Registered
76th of 101
by date

Among the 101 studies in Influenza, Human by Novartis, this one is the 85th largest by enrollment of the 97 interventional ones that give a count, is one of 5 that started in 2011, is one of 42 in phase 2, and was the 76th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

None of the 101 studies in Influenza, Human by Novartis is open now. The open studies under Influenza, Human, anywhere →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 101 studies in Influenza, Human by Novartis as a file.
02

Study summary

This study will evaluate the safety and immunogenicity of a sub-unit, adjuvanted Influenza Vaccine Administered to Elderly Subjects.

03

Conditions studied

  • Seasonal Influenza

Browse trials for

Keywords

  • Seasonal Influenza, vaccine
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Males and females volunteers of 65 years of age or older, mentally competent, willing and able to give written prior to study entry.
  • Individuals able to comply with all the study requirements.
  • Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
  • Written informed consent must be obtained for all the subjects before enrollment into the study after the nature of the study has been explained.

Key Exclusion Criteria:

  • Individuals with any serious chronic or acute disease.
  • Individuals with history of any anaphylactic reaction and/or serious allergic reaction following a vaccination.
  • Individuals with known or suspected impairment/alteration of immune function.
  • Individuals with known or suspected history of drug or alcohol abuse.
  • Individuals with a bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject.
  • Individuals within the past 6 months, they have: had any seasonal or pandemic laboratory confirmed influenza disease; received any seasonal or pandemic influenza vaccine.
  • Individuals with any acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the last 7 days.
  • Individuals that have experienced fever (i.e., axillary temperature ≥38°C) within the last 3 days of intended study vaccination.
  • Individuals participating in any clinical trial with another product 4 weeks prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.
  • Individuals who received any other vaccines within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccines.
  • Individuals who are part of study personnel or close family members conducting this study.
  • > 35 kg/m2.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Other
    Sub unit, Inactivated, MF59C.1 Adjuvanted Influenza Vaccine

    No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit

    Biological: Seasonal Influenza Vaccine

Interventions

  • BiologicalSeasonal Influenza Vaccine

    This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One Vaccination of FLUAD

    Immunogenicity was measured as the percentage of participants who achieved seroconversion or significant increase in single radial hemolysis (SRH) area, against each of the three vaccine strains, three weeks after vaccination (day 22), evaluated using SRH assay. Seroconversion: proportion of participants with negative pre-vaccination serum and a post-vaccination serum area ≥ 25 mm2. Significant increase: proportion of participants with at least a 50% increase in area from positive pre-vaccination serum. Seroconversion or significant increase: proportion of participants with either seroconversion or significant increase. The European (Committee for Medicinal Products for Human Use \[CHMP\]) criterion is met, if percentage of participants achieving seroconversion or significant increase in SRH area is 30% (≥65 years).

    Time frame: day 22

  2. Geometric Mean Ratio of Participants Against Each of the Three Vaccine Strains After One Vaccination of FLUAD

    Geometric mean ratio (GMR) of participants was calculated as the ratio of post-vaccination to pre-vaccination SRH geometric mean areas (GMAs), directed against each of the three vaccine strains, three weeks after FLUAD vaccination (day 22). The CHMP criterion was met if the geometric mean increase (GMR, day 22/day 1) in SRH antibody area is \>2.0 (≥65 years).

    Time frame: day 22

  3. Percentage of Participants Who Achieved SRH Area ≥25mm2 Against Each of the Three Vaccine Strains After One Vaccination of FLUAD

    Immunogenicity was measured as the percentage of participants achieving SRH area ≥25 mm2 against each of the three vaccine strains at baseline (day 1) and three weeks after FLUAD vaccination (day 22). This criterion is met according to CHMP guideline if percentage of participants achieving SRH area ≥25 mm2 is 60% (≥65 years).

    Time frame: day 22

Secondary outcomes

  1. Number of Participants Who Reported Solicited Local and Systemic Reactions

    Safety was assessed for participants who reported solicited local and systemic reactions from day 1 up to and including day 4 after the FLUAD vaccination.

    Time frame: 1 to 4 days post-vaccination

07

Results

Posted Jan 28, 2016

Participant flow

Overall, 63 participants were ≥65 years of age were enrolled at 4 sites in Italy.

Participant flow — Overall Study
MilestoneFLUAD
Started63
Completed62
Not completed1
Withdrew: Premature withdrawal1

Outcome measures

PrimaryPercentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One Vaccination of FLUAD

Immunogenicity was measured as the percentage of participants who achieved seroconversion or significant increase in single radial hemolysis (SRH) area, against each of the three vaccine strains, three weeks after vaccination (day 22), evaluated using SRH assay. Seroconversion: proportion of participants with negative pre-vaccination serum and a post-vaccination serum area ≥ 25 mm2. Significant increase: proportion of participants with at least a 50% increase in area from positive pre-vaccination serum. Seroconversion or significant increase: proportion of participants with either seroconversion or significant increase. The European (Committee for Medicinal Products for Human Use \[CHMP\]) criterion is met, if percentage of participants achieving seroconversion or significant increase in SRH area is 30% (≥65 years).

Time frame:
day 22
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One Vaccination of FLUAD
Percentage of participantsFLUAD
A/H1N1 (N= 62)69 (56 to 80)
A/H3N2 (N= 62)50 (37 to 63)
B (N= 62)26 (16 to 38)
SecondaryNumber of Participants Who Reported Solicited Local and Systemic Reactions

Safety was assessed for participants who reported solicited local and systemic reactions from day 1 up to and including day 4 after the FLUAD vaccination.

Time frame:
1 to 4 days post-vaccination
Reported as:
Number · Number of participants
Number of Participants Who Reported Solicited Local and Systemic Reactions
Number of participantsFLUAD
Injection site ecchymosis (N= 62)3
Injection site erythema (N= 62)7
Injection site induration (N= 62)4
Injection site swelling (N= 62)7
Injection site pain (N= 62)21
Chills Shivering (N= 62)4
Malaise (N= 62)3
Myalgia (N= 62)6
Arthralgia (N= 62)4
Headache (N= 62)4
Sweating (N= 62)1
Fatigue (N= 62)2
Fever (≥38°C) (N= 61)0
PrimaryGeometric Mean Ratio of Participants Against Each of the Three Vaccine Strains After One Vaccination of FLUAD

Geometric mean ratio (GMR) of participants was calculated as the ratio of post-vaccination to pre-vaccination SRH geometric mean areas (GMAs), directed against each of the three vaccine strains, three weeks after FLUAD vaccination (day 22). The CHMP criterion was met if the geometric mean increase (GMR, day 22/day 1) in SRH antibody area is \>2.0 (≥65 years).

Time frame:
day 22
Reported as:
Geometric mean · Ratio
Geometric Mean Ratio of Participants Against Each of the Three Vaccine Strains After One Vaccination of FLUAD
RatioFLUAD
A/H1N1 (N= 62)2.54 (2.1 to 3.07)
A/H3N2 (N= 62)1.9 (1.63 to 2.2)
B (N= 62)1.36 (1.21 to 1.53)
PrimaryPercentage of Participants Who Achieved SRH Area ≥25mm2 Against Each of the Three Vaccine Strains After One Vaccination of FLUAD

Immunogenicity was measured as the percentage of participants achieving SRH area ≥25 mm2 against each of the three vaccine strains at baseline (day 1) and three weeks after FLUAD vaccination (day 22). This criterion is met according to CHMP guideline if percentage of participants achieving SRH area ≥25 mm2 is 60% (≥65 years).

Time frame:
day 22
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved SRH Area ≥25mm2 Against Each of the Three Vaccine Strains After One Vaccination of FLUAD
Percentage of participantsFLUAD
A/H1N1 (N= 62)89 (78 to 95)
A/H3N2 (N= 62)69 (56 to 80)
B (N= 62)94 (84 to 98)

Adverse events

Collected over From Day 1 through Day 22.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FLUAD—0/63 (0%)6/63 (9.5%)
Most frequent other events
Most frequent other events
EventFLUAD
Injection site erythemaGeneral disorders3/63
Injection site haemorrhageGeneral disorders2/63
Injection site indurationGeneral disorders2/63
Injection site painGeneral disorders2/63
Injection site swellingGeneral disorders2/63
ArthralgiaMusculoskeletal and connective tissue disorders2/63
MyalgiaMusculoskeletal and connective tissue disorders2/63
MastoiditisInfections and infestations1/63

Baseline characteristics

Baseline analysis population was defined as all participants who were enrolled into the study.

Age, Continuous
Age, Continuous(Years)FLUAD
Mean73.2 ± 5.2
Sex: Female, Male
Sex: Female, Male(Participants)FLUAD
Female31
Male32
08

Study locations

6 sites
  • Dipartimento di Medicina e Scienze dell'Invecchiamento, Università G. D'Annunzio
    Via Dei Vestini, Chieti 66100, Italy
  • Department of "Scienze della Salute" University of Genova Via Pastore 1
    Genova, 16132, Italy
  • Satellite: "ASL Lanciano - Vasto", sede legale Via S Spaventa 37
    Lanciano, 66034, Italy
  • Satellite: "Distretto Sanitario di Base di Fossacesia" in Via Polidoro-Vasto
    Lanciano, Italy
  • Vaccine and Immunotherapy Research Center Department of Infectious and Tropical Diseases San Raffaele Scientific Institute Via Stamira d'Ancona 20
    Milano, 20127, Italy
  • Department of "malattie infettive" Ospedale San Gerardo, via Pergolesi 33
    Monza, 20052, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2011
First posted
Apr 28, 2011
Start
May 2011
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Jan 28, 2016
Last update
Apr 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01344057
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Apr 28, 2011
Start date
May 2011
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Jan 28, 2016
Last update
Apr 28, 2023
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion